The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Jounce Therapeutics; Neophore; PapGene, Inc.; Personal Genome Diagnostics; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Caris Life Sciences; Cell Design Labs; Genocea Biosciences; Lyndra Therapeutics; Merck; Neophore; Personal Genome Diagnostics; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Travel, Accommodations, Expenses - Merck
 
Dung T. Le
Honoraria - Merck
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Curegenix; Medivir; Merck
Patents, Royalties, Other Intellectual Property - Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".
 
Tae Won Kim
Employment - Asan Medical Center
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); Sanofi (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Ravit Geva
Leadership - Pyxis
Honoraria - Bristol-Myers Squibb; Janssen; Medison; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bayer; BOL Pharma; MSD; Novartis
Patents, Royalties, Other Intellectual Property - Options, BOL Pharma
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Medison; Merck Serono
 
Dirk Jaeger
Consulting or Advisory Role - Amgen (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Hiroki Hara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kiowa Kirin; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Lilly; MSD; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst)
 
Matthew E. Burge
Stock and Other Ownership Interests - Bristol-Myers Squibb; coclear; CSL Limited; Gilead Sciences; pfizer
Honoraria - Amgen; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Amgen; ipsen; Roche
Patents, Royalties, Other Intellectual Property - funding for an investigator initiated prospective trial (Inst)
Travel, Accommodations, Expenses - Amgen; Roche; Roche
 
Bert H. O'Neil
Honoraria - Merck
 
Petr Kavan
Honoraria - Amgen; Bayer; Ipsen; Novartis; Pfizer
Consulting or Advisory Role - Amgen; Celgene; LEO Pharma; Novartis; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Ipsen; NOVARTIS; Pfizer; Taiho Pharmaceutical
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)
 
Rosine Guimbaud
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Novartis; Pierre Fabre; Roche; SERVIER
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; MSD Oncology; Novartis; Ono Pharmaceutical; Sysmex; Takeda
 
Elena Elez
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Merck Serono; Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche; Sanofi
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - IKF Klinische Krebsforschung
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Sharp & Dohme; Nordic Bioscience; Roche
Speakers' Bureau - AIO gGmbH; Celgene; Forum für Medizinische Fortbildung; Lilly; MCI group; Nordic Bioscience
Research Funding - Celgene; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Lilly; Medac; Merck; Roche; Sanofi; Vifor Pharma
 
Patrick M Boland
Honoraria - Sirtex Medical
Consulting or Advisory Role - Bayer; Ipsen; Ipsen
Research Funding - Advaxis (Inst); Athenex (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Genentech/Roche (Inst); Ipsen (Inst); Merck (Inst)
 
Yi Cui
No Relationships to Disclose
 
Carlos Alberto Mayo
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Patricia Marinello
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Thierry Andre
Honoraria - AMGEN; Bayer; Bristol-Myers Squibb; Pierre Fabre; Roche/Genentech; Sanofi; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Clovis Oncology; Gastrointestinal Cancers Advice; Gastrointestinal Cancers Advice; HalioDX; MSD Oncology; Roche/Genentech; SERVIER; Tesaro
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche/Genentech; Ventana Medical Systems